• TREATMENT

    Phase II trial shows adjuvant mFOLFOXIRI feasible after oligometastatic CRC resection

    In the FANTASTIC trial, 74% of 39 patients completed eight cycles of adjuvant mFOLFOXIRI after metastasectomy; the regimen improved recurrence-free survival compared with standard of care (HR 0.44), with a trend toward benefit in ctDNA-positive patients. (BJS Open)